Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks
– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –
– IgAN is a progressive kidney disease that is typically diagnosed in young adults and up to 50% of people progress to kidney failure within 20 years, requiring dialysis or transplantation –
– Interim data will be presented at an upcoming medical meeting and shared with health authorities –
Login to comment